December 1, 2016 - By Ruchi Gupta · 0 Comments
The stock of Dicerna Pharmaceuticals Incorporated (NASDAQ:DRNA) registered an increase of 13.87% in short interest. DRNA’s total short interest was 486,000 shares in December as published by FINRA. Its up 13.87% from 426,800 shares, reported previously. With 104,700 shares average volume, it will take short sellers 5 days to cover their DRNA’s short positions. The short interest to Dicerna Pharmaceuticals Incorporated’s float is 3.89%. About 48,817 shares traded hands. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 38.43% since April 28, 2016 and is downtrending. It has underperformed by 44.36% the S&P500.
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid interference biopharmaceutical company. The company has a market cap of $62.25 million. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It currently has negative earnings. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Insitutional Activity: The institutional sentiment decreased to 0.56 in 2016 Q2. Its down 0.20, from 0.76 in 2016Q1. The ratio dropped, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Moreover, Fmr Ltd Company has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 3.11 million shares. Susquehanna Gru Limited Liability Partnership last reported 0% of its portfolio in the stock. Tfs Lc last reported 30,429 shares in the company. Eventide Asset Mngmt Limited Liability Co reported 377,000 shares or 0.07% of all its holdings. D E Shaw And Com has invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). The Connecticut-based Bourgeon Capital Mngmt Limited has invested 0.04% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Blackrock Mgmt Limited Co last reported 2,582 shares in the company. Paloma Partners Mngmt accumulated 60,979 shares or 0% of the stock. Deutsche National Bank & Trust Ag has 68,918 shares for 0% of their US portfolio. The California-based Dafna Capital Llc has invested 0.28% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Creative Planning last reported 0% of its portfolio in the stock. Dimensional Fund Advsrs Limited Partnership accumulated 0% or 34,273 shares. Art Advsrs Lc has 0.01% invested in the company for 56,763 shares. Tower Ltd Limited Liability Company (Trc) has 0% invested in the company for 1,220 shares. Jacobs Levy Equity Management Inc last reported 0.01% of its portfolio in the stock.
Insider Transactions: Since November 14, 2016, the stock had 1 insider purchase, and 1 sale for $38,987 net activity. 33,100 shares with value of $122,643 were bought by FAMBROUGH DOUGLAS on Monday, November 14. LANGER DENNIS sold 23,766 shares worth $83,656.
Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Monday, August 10 with “Buy”. The firm has “Buy” rating given on Thursday, June 30 by Stifel Nicolaus. The firm earned “Outperform” rating on Tuesday, September 8 by Cowen & Co. The firm has “Neutral” rating by Chardan Capital Markets given on Thursday, June 30. On Monday, August 15 the stock rating was maintained by Chardan Capital Markets with “Neutral”. Stifel Nicolaus maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) rating on Tuesday, May 10. Stifel Nicolaus has “Buy” rating and $16 price target. The firm has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus.
Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta